

10/19/92
"CRE"

03-22-1999



SHEET

ONLY

No Check

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

Tab settings

100989289

attached original documents or copy thereof.

To the Honorable Commissioner

1. Name of conveying party(ies):

Sandoz Pharmaceuticals Corporation

- Individual(s)
- General Partnership
- Corporation-State-Delaware
- Other
- Association
- Limited Partnership

Additional name(s) of conveying party(ies) attached? Yes No

2. Name and address of receiving party(ies):

Name: Novartis Pharmaceuticals Corporation

Internal Address: _____

Street Address: 59 Route 10

City: East Hanover State: NJ ZIP: 07936

- Individual(s) citizenship
- Association
- General Partnership
- Limited Partnership
- Corporation-State Delaware
- Other

If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No

(Designations must be a separate document from Assignment)

Additional name(s) & address(es) attached? Yes No

3. Nature of conveyance:

- Assignment
- Security Agreement
- Other
- Merger
- Change of Name

Execution Date: December 23, 1996

4. Application number(s) or registration number(s):

A. Trademark Application No.(s)

See Attachment A

B. Trademark registration No.(s)

See Attachment B

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Barry A. Solomon, Esq.

Internal Address: Novartis Corporation

Street Address: 564 Morris Avenue

City: Summit State: NJ ZIP: 07901

6. Total number of applications and registrations involved:

119

7. Total fee (37 CFR 3.41):..... \$ 2990.00

Enclosed

Authorized to be charged to deposit account

8. Deposit account number:

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copies are true copy of the original document.

Barry A. Solomon
Name of Person Signing

Barry A. Solomon
Signature

10/16/96
Date

Total number of pages comprising cover sheet

OMB No. 0651-0011 (exp. 4/94)

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks
Box Assignments
Washington, D.C. 20231

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Washington, D.C. 20503.

**SANDOZ PHARMACEUTICALS CORPORATION to NOVARTIS
PHARMACEUTICALS CORPORATION
Trademark Applications**

MARK	APPLN. NO.	APPLN. DATE	CLASS
LOMAX	A.N. 74/057950	5/11/90	5

Attachment A

**TRADEMARK
REEL: 1864 FRAME: 0890**

**SANDOZ PHARMACEUTICALS CORPORATION to NOVARTIS
PHARMACEUTICALS CORPORATION
Trademark Registrations**

MARK	REG. NO.	REG. DATE	CLASS
1 SCRIPT WON	710454	1/31/61	5
ALPID	1127776	12/18/79	5
ANCA	711128	2/14/61	5
ARTHREX	1191044	3/2/82	5
ASBRON	773519	7/21/64	5
BELLADENAL-S	1085858	2/21/78	5
BELLAFOLINE	385186	2/18/41	5
BELLARGAL-S	1085859	2/21/78	5
BEPHAN	666503	9/2/58	5
BIAQUIN	1214657	11/2/82	5
BIARISON	1097187	7/25/78	5
BINPAK	1101925	9/12/78	5
CAFERGOT	528520	8/1/50	5
CALURIN	689032	12/1/59	5
CEDILANID	367897	5/30/39	5
CHEXIT	767739	3/31/64	5
Column Design	1659266	10/1/91	16
CONTROLPAK	1101891	9/12/78	5
D.H.E. 45	538654	2/27/51	5
D.H.E.-HEP	1120349	6/19/79	5
D.H.E.-HEPRARIN	1124386	8/28/79	5
DELTOIN	738171	9/25/62	5
DIAPID	831722	7/11/67	5
DORASE	728447	3/13/62	5
DOR-C	870353	6/3/69	5
DORMETHAN	703387	8/23/60	5
DORSEY	1170870	9/29/81	5
DORSEY	1222314	1/4/83	5
DYNACIRC	1413953	10/21/86	5
DYNACIRC	1504573	9/20/88	5
DYNACIRC CR	1687539	5/19/92	5
ENTULIC	1168885	9/15/81	5
ESTULIC	1127775	12/18/79	5
FELAMINE	379319	7/9/40	5
FIOGESIC	850468	6/11/68	5
FIORICET	1080168	12/27/77	5
FIORINAL	560929	7/1/52	5
GETRIC	683154	8/11/59	5
GLYSENNID	395669	6/2/42	5
GYNERGEN	351658	11/2/37	5
HYDANTAL	402905	8/24/43	5
INLAY-TABS	1001728	1/14/75	5

Attachment B

**SANDOZ PHARMACEUTICALS CORPORATION to NOVARTIS
PHARMACEUTICALS CORPORATION**

Trademark Registrations

MARK	REG. NO.	REG. DATE	CLASS
INLAY-TABS	1005204	2/25/75	5
IPESANDRINE	401215	4/27/43	5
KANULASE	705161	10/4/60	5
KANUMODIC	719573	8/8/61	5
KLORVRESS	944495	10/10/72	5
LIDANAR	737456	9/11/62	5
LIPORIDE	685457	9/22/59	5
LIPOSAL	686827	10/20/59	5
LOMAX	1666264	11/26/91	5
MELLARIL	687095	10/27/59	5
MELLARIL-S	1132052	4/1/80	5
MENTHO-FOAM	755356	8/27/63	5
MEPRODIL	695197	3/29/60	5
MESANTOIN	426478	12/24/46	5
METAPREL	993337	9/24/74	5
METHERGINE	400893	4/6/43	5
MIGRAMIN	1109091	12/19/78	5
NEO-"CALGLUCON"	337832	8/18/36	5
NEO-CAFERGOT	723514	11/7/61	5
NEO-CAL	820209	12/13/66	5
NEOCITRAN	870349	6/3/69	5
NITE LIGHT and Design	1576009	1/9/90	5
ONE OF THE RECOMMENDABLES	1072096	8/30/77	5
PALEROL	711454	2/21/61	5
PAMELOR	906503	1/26/71	5
PANOCET	1115141	3/20/79	5
PANOLID	732664	6/12/62	5
PRESTULIC	1116545	4/17/79	5
PROVAL #3	737447	9/11/62	5
RENORMAX	1489848	5/31/88	5
RESODEX	1129138	1/15/80	5
RESTORIL	1038108	4/20/76	5
RESTORIL	1076802	4/20/76	5
RHINALGAN	698866	6/7/60	5
SANDOMUN	1214665	11/2/82	5
SANDOPAK	890794	5/12/70	5
SANDOPTAL	820210	12/13/66	5
SANDOXAL	727904	2/27/62	5
SANOEX	928132	2/1/72	5
SANSERT	707129	11/15/60	5
SERENTIL	802249	2/8/66	5
Shaking Hands Design	1592279	4/17/90	35
SHEERTABS	719424	8/1/61	5

Attachment B

**SANDOZ PHARMACEUTICALS CORPORATION to NOVARTIS
PHARMACEUTICALS CORPORATION**

Trademark Registrations

MARK	REG. NO.	REG. DATE	CLASS
SIGPAK	1097186	7/25/78	5
Sleeping Woman Design	1615414	10/2/90	5
SNAPTABS	1537187	5/2/89	5
SODEX	1143086	12/16/80	5
SPACETABS	839040	11/21/67	5
STETRIC	656351	12/31/57	5
Stick Figure Design (Shaded)	1612642	9/11/90	5
Sun and Moon Design	1466938	12/1/87	5
Sun Design	1604313	7/3/90	5
SYNTOCINON	637952	12/4/56	5
SYNTOCINON	1138191	7/29/80	5
TAIN	708963	12/27/60	5
TANOREX	747500	4/2/63	5
TAVIDRIN	1101926	9/12/78	5
TAVIGEST	1101924	9/12/78	5
TELON	740509	11/13/62	5
THE RECOMMENDABLES	1072095	8/3/77	5
Three Profiles and Design	1394624	5/27/86	5
TICHOLIN	683155	8/11/59	5
TORECAN	708678	12/20/60	5
TREST	734834	7/24/62	5
TRIATHAN	683562	8/18/59	5
TRIATUSSIC	679509	6/2/59	5
TRISULFAMINIC	674846	3/3/59	5
TRUE-DOSE	1351537	7/30/85	10
TRUE-DOSE	1576256	1/9/90	10
TUSSAGESIC	714324	4/25/61	5
TUSSAMINIC	666219	8/26/58	5
URSINUS	699324	6/14/60	5
V & Device	1150755	4/14/81	3
VISKEN 5 and Heart Design	1541166	5/30/89	5
WARDPAK	897695	9/1/70	5
Wave Design	1480436	3/15/88	5

Attachment B

STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 09:00 AM 12/28/1998
360384917 - 0691007

CERTIFICATE OF AMENDMENT
OF
CERTIFICATE OF INCORPORATION

SANDOZ PHARMACEUTICALS CORPORATION, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY:

FIRST: That the Board of Directors of said corporation, by the unanimous written consent of its members, filed with the minutes of the Board, adopted a resolution proposing and declaring advisable the following amendment to the Certificate of Incorporation of said corporation:

RESOLVED, that the Certificate of Incorporation of Sandoz Pharmaceuticals Corporation be amended by changing the Article numbered "First" thereof so that, as amended, said Article shall be and read as follows:

"The name of this Corporation is Novartis Pharmaceuticals Corporation."

SECOND: That in lieu of a meeting and vote of stockholders, the stockholder has given unanimous written consent to said amendment in accordance with the provisions of section 228 of the General Corporation Law of the State of Delaware.

THIRD: That the aforesaid amendment was duly adopted in accordance with the applicable provisions of sections 242 and 228 of the General Corporation Law of the State of Delaware.

IN WITNESS WHEREOF, said SANDOZ PHARMACEUTICALS CORPORATION has caused this certificate to be signed by Edgar J. Fullagar, its Chairman of the Board and attested by Herbert J. Brennan, its Secretary this 23 day of December, 1998.

SANDOZ PHARMACEUTICALS CORPORATION

By Edgar J. Fullagar
Chairman of the Board

ATTEST:
By Herbert J. Brennan

*State of Delaware**Office of the Secretary of State* PAGE 1

I, EDWARD J. FREEL, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "SANDOZ PHARMACEUTICALS CORPORATION", CHANGING ITS NAME FROM "SANDOZ PHARMACEUTICALS CORPORATION" TO "NOVARTIS PHARMACEUTICALS CORPORATION", FILED IN THIS OFFICE ON THE TWENTY-SIXTH DAY OF DECEMBER, A.D. 1996, AT 9 O'CLOCK A.M.



Edward J. Freel

Edward J. Freel, Secretary of State

0691007 8100

981032812

AUTHENTICATION: 8888060

DATE: 01-27-98